Product Images Losartan Potassium

This appears to be a graph or chart showing the percentage of patients who achieved the primary endpoint in a study of two medications: Atenolol and Losartan potassium. It also includes an adjusted risk reduction percentage and the study duration in months.*

This text seems to be a chart or table showing the percentage of patients with fatal/non-fatal stroke for two different medications, Atenolol and Losartan potassium. The adjusted risk reduction is also provided, along with a p-value. The table also includes study months from 6 to 66. Without additional context or information, it is difficult to provide a more detailed description or analysis.*

This is a table displaying the results of a study comparing the effectiveness of Losartan K and Atenolol in treating stroke. The data is broken down by age group, gender, race, diabetes status, and history of CVD. The results indicate that Losartan K had a slight advantage over Atenolol in reducing the incidence of primary composite stroke (fatal and non-fatal). The data has been adjusted for baseline Framingham risk score and level of electrocardiographic eft ventricular hypertrophy.*

This is a table showing the risk reduction percentage of a drug called Losartan Potassium in comparison to a placebo. The risk reduction achieved by the drug is 16.1% with a significance level of 0.022. However, the context and the event being studied are not available.*

This is a description of a medication. The medication is listed as "Losartan Potassium," and is in tablet form with a strength of 50 mg. The manufacturer is Teva, and the lot number is LoT89L211. The expiration date is listed as November 2014. The packaging includes a code labeled as UB52914SN19 and a label indicating that it is for prescription use only. The remaining text is not legible due to possible errors.*